{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:33:08Z","timestamp":1785367988530,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dantrolene was introduced for treatment of malignant hyperthermia. It also has antiarrhythmic properties and may thus be an alternative to amiodarone for the treatment of ventricular fibrillation (VF). Aim of this study was to compare the return of spontaneous circulation (ROSC) with dantrolene and amiodarone in a pig model of cardiac arrest. VF was induced in anesthetized pigs. After 8\u2009min of untreated VF, chest compressions and ventilation were started and one of the drugs (amiodarone 5\u2009mg\u2009kg<jats:sup>\u22121<\/jats:sup>, dantrolene 2.5\u2009mg\u2009kg<jats:sup>\u22121<\/jats:sup> or saline) was applied. After 4\u2009min of initial CPR, defibrillation was attempted. ROSC rates, hemodynamics and cerebral perfusion measurements were measured. Initial ROSC rates were 7 of 14 animals in the dantrolene group vs. 5 of 14 for amiodarone, and 3 of 10 for saline). ROSC persisted for the 120\u2009min follow-up in 6 animals in the dantrolene group, 4 after amiodarone and 2 in the saline group (n.s.). Hemodynamics were comparable in both dantrolene group amiodarone group after obtaining ROSC. Dantrolene and amiodarone had similar outcomes in our model of prolonged cardiac arrest, However, hemodynamic stability was not significantly improved using dantrolene. Dantrolene might be an alternative drug for resuscitation and should be further investigated.<\/jats:p>","DOI":"10.1038\/srep40875","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T10:37:37Z","timestamp":1484735857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dantrolene versus amiodarone for cardiopulmonary resuscitation: a randomized, double-blinded experimental study"],"prefix":"10.1038","volume":"7","author":[{"given":"Thomas","family":"Wiesmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennik","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Eschbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Irqsusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Steinfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinnerk","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"BFsrep40875_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.113.005443","volume":"129","author":"N Zamiri","year":"2014","unstructured":"Zamiri, N. et al. Dantrolene improves survival after ventricular fibrillation by mitigating impaired calcium handling in animal models. Circulation 129, 875\u2013885 (2014).","journal-title":"Circulation"},{"key":"BFsrep40875_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.113.007657","volume":"129","author":"DM Roden","year":"2014","unstructured":"Roden, D. M. & Knollmann, B. C. Dantrolene: from better bacon to a treatment for ventricular fibrillation. Circulation 129, 834\u2013836 (2014).","journal-title":"Circulation"},{"key":"BFsrep40875_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.resuscitation.2009.05.015","volume":"80","author":"C Kill","year":"2009","unstructured":"Kill, C. et al. Basic life support with four different compression\/ventilation ratios in a pig model: the need for ventilation. Resuscitation 80, 1060\u20131065 (2009).","journal-title":"Resuscitation"},{"key":"BFsrep40875_CR4","doi-asserted-by":"publisher","first-page":"e0127759","DOI":"10.1371\/journal.pone.0127759","volume":"10","author":"C Kill","year":"2015","unstructured":"Kill, C. et al. Chest Compression Synchronized Ventilation versus Intermitted Positive Pressure Ventilation during Cardiopulmonary Resuscitation in a Pig Model. PLoS ONE 10, e0127759 (2015).","journal-title":"PLoS ONE"},{"key":"BFsrep40875_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.resuscitation.2015.07.038","volume":"95","author":"KG Monsieurs","year":"2015","unstructured":"Monsieurs, K. G. et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 1. Executive summary. Resuscitation 95, 1\u201380 (2015).","journal-title":"Resuscitation"},{"key":"BFsrep40875_CR6","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1097\/CCM.0b013e3182a63fa0","volume":"42","author":"C Kill","year":"2014","unstructured":"Kill, C. et al. Mechanical ventilation during cardiopulmonary resuscitation with intermittent positive-pressure ventilation, bilevel ventilation, or chest compression synchronized ventilation in a pig model. Crit. Care Med. 42, e89\u201395 (2014).","journal-title":"Crit. Care Med."},{"key":"BFsrep40875_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10557-015-6604-7","volume":"29","author":"G Karlis","year":"2015","unstructured":"Karlis, G. et al. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. Cardiovasc Drugs Ther 29, 425\u2013431 (2015).","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFsrep40875_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/aas.12226","volume":"58","author":"G Karlis","year":"2014","unstructured":"Karlis, G. et al. Effects of early amiodarone administration during and immediately after cardiopulmonary resuscitation in a swine model. Acta Anaesthesiol Scand 58, 114\u2013122 (2014).","journal-title":"Acta Anaesthesiol Scand"},{"key":"BFsrep40875_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"JG D\u2019Alessio","year":"2007","unstructured":"D\u2019Alessio, J. G. et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods 39, 175\u2013191 (2007).","journal-title":"Behavior research methods"},{"key":"BFsrep40875_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1476-5381.1970.tb09892.x","volume":"39","author":"R Charlier","year":"1970","unstructured":"Charlier, R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br. J. Pharmacol. 39, 668\u2013674 (1970).","journal-title":"Br. J. Pharmacol"},{"key":"BFsrep40875_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resuscitation.2003.12.003","volume":"61","author":"EP Tsagalou","year":"2004","unstructured":"Tsagalou, E. P. et al. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone\u2013an experimental study. Resuscitation 61, 83\u201389 (2004).","journal-title":"Resuscitation"},{"key":"BFsrep40875_CR12","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1161\/CIRCULATIONAHA.105.592121","volume":"113","author":"W Tang","year":"2006","unstructured":"Tang, W. et al. One-shock versus three-shock defibrillation protocol significantly improves outcome in a porcine model of prolonged ventricular fibrillation cardiac arrest. Circulation 113, 2683\u20132689 (2006).","journal-title":"Circulation"},{"key":"BFsrep40875_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.resuscitation.2010.04.023","volume":"81","author":"X-F Ji","year":"2010","unstructured":"Ji, X.-F., Li, C.-S., Wang, S., Yang, L. & Cong, L.-H. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation 81, 1031\u20131036 (2010).","journal-title":"Resuscitation"},{"key":"BFsrep40875_CR14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1514204","volume":"374","author":"PJ Kudenchuk","year":"2016","unstructured":"Kudenchuk, P. J. et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. 374(18), 1711\u201322, doi: 10.1056\/NEJMoa1514204 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep40875_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","volume":"59","author":"T Krause","year":"2004","unstructured":"Krause, T., Gerbershagen, M. U., Fiege, M., Weisshorn, R. & Wappler, F. Dantrolene\u2013a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59, 364\u2013373 (2004).","journal-title":"Anaesthesia"},{"key":"BFsrep40875_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1742-7843.2007.00156.x","volume":"102","author":"RT Sudo","year":"2008","unstructured":"Sudo, R. T., Carmo, P. L. D., Trachez, M. M. & Zapata-Sudo, G. Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle. Basic Clin. Pharmacol. Toxicol. 102, 308\u2013316 (2008).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"BFsrep40875_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00005344-198205000-00006","volume":"4","author":"WB Gough","year":"1982","unstructured":"Gough, W. B., Zeiler, R. H., Barreca, P. & El-Sherif, N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J. Cardiovasc. Pharmacol. 4, 375\u2013380 (1982).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFsrep40875_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/14740331003586811","volume":"9","author":"PF Souney","year":"2010","unstructured":"Souney, P. F., Cooper, W. D. & Cushing, D. J. PM101: intravenous amiodarone formulation changes can improve medication safety. Expert Opin Drug Saf 9, 319\u2013333 (2010).","journal-title":"Expert Opin Drug Saf"},{"key":"BFsrep40875_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bja\/aew126","volume":"116","author":"F de Wit","year":"2016","unstructured":"de Wit, F. et al. The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances. British Journal of Anaesthesia 116, 784\u2013789 (2016).","journal-title":"British Journal of Anaesthesia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40875","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:40:54Z","timestamp":1671831654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,9]]}},"alternative-id":["BFsrep40875"],"URL":"https:\/\/doi.org\/10.1038\/srep40875","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]},"assertion":[{"value":"15 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TW is involved with B. Braun (advisory board) HW is involved with Teleflex, Vygon an B. Braun (speaker fees), TS is involved with Teleflex, Vygon and B.Braun (advisory board). None of the other authors declared any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40875"}}